ERBB2 and breast carcinoma: Recent years have witnessed increasing clinical recognition of HER2-low breast cancer as a distinct therapeutic subtype, stimulating interest in exploring this entity within the GC landscape (Modi et al., 2022; Tara et al., 2020; Yu et al., 2023).